Icecure Medical Ltd has a consensus price target of $3.64 based on the ratings of 4 analysts. The high is $5.65 issued by Brookline Capital on February 2, 2022. The low is $2.9 issued by Alliance Global Partners on March 20, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on July 2, 2024, June 5, 2024, and May 29, 2024, respectively. With an average price target of $3 between HC Wainwright & Co., there's an implied 258.12% upside for Icecure Medical Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/02/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
06/05/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
05/29/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
04/16/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
04/04/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
03/20/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
03/20/2024 | Buy Now | 246.19% | Alliance Global Partners | Ben Haynor | $1.9 → $2.9 | Maintains | Buy | Get Alert |
03/05/2024 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
11/29/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
09/06/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
08/15/2023 | Buy Now | 377.5% | Alliance Global Partners | Ben Haynor | $4.25 → $4 | Maintains | Buy | Get Alert |
08/15/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
07/25/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
06/01/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
05/23/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | Buy → Buy | Get Alert |
03/28/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Reiterates | → Buy | Get Alert |
03/20/2023 | Buy Now | 258.12% | HC Wainwright & Co. | Yi Chen | → $3 | Initiates | → Buy | Get Alert |
10/25/2022 | Buy Now | 258.12% | Maxim Group | Anthony Vendetti | → $3 | Initiates | → Buy | Get Alert |
02/02/2022 | Buy Now | 574.47% | Brookline Capital | Kemp Dolliver | → $5.65 | Initiates | → Buy | Get Alert |
09/22/2021 | Buy Now | 1630.93% | Alliance Global Partners | Ben Haynor | — | Initiates | → Buy | Get Alert |
The latest price target for Icecure Medical (NASDAQ:ICCM) was reported by HC Wainwright & Co. on July 2, 2024. The analyst firm set a price target for $3.00 expecting ICCM to rise to within 12 months (a possible 258.12% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for Icecure Medical (NASDAQ:ICCM) was provided by HC Wainwright & Co., and Icecure Medical reiterated their buy rating.
There is no last upgrade for Icecure Medical
There is no last downgrade for Icecure Medical.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Icecure Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Icecure Medical was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
While ratings are subjective and will change, the latest Icecure Medical (ICCM) rating was a reiterated with a price target of $3.00 to $3.00. The current price Icecure Medical (ICCM) is trading at is $0.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.